Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Gencor Pacific Group | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
INTRODUCTION: Iron is a vital nutrient for many physiological processes including DNA production, oxygen transport and neuronal processes. However, several factors limit iron absorption including: limited bioavailability of iron (dietary or supplementation sources), can be subject to dietary iron inhibitors (e.g. calcium). Excess iron can cause cellular oxidative stress in the body.
Curcumin is an active component found in turmeric, known for its anti-oxidant and anti-inflammatory properties. Co-administration of iron and curcumin may influence iron, inflammatory status and/or neurotrophic markers in the body.
Intervention study with five parallel treatment groups in a randomised, double-blind, placebo-controlled design.
Study population: Healthy Participants (Male or Female) will receive daily supplements (active or equivalent placebos) for 6 weeks (42 days)
Biological samples (blood and urine samples) are collected at baseline visit (day 1), mid-point (day 21) and end-point (day 42). In addition, pertinent questionnaires (Visual Analogue Scale-Fatigue [VAS-F] and oral iron supplement questionnaire will be collected at the aforementioned time points.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FS65_Curc | Active Comparator | Ferrous Sulphate (65 mg/day elemental iron) and Curcumin 500 mg/day |
|
| FS65_Plac | Placebo Comparator | Ferrous Sulphate (65 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose]) |
|
| FS0_Plac | Placebo Comparator | Placebo (Ferrous Sulphate placebo [cellulose]) and Placebo (Curcumin placebo [cellulose]) |
|
| FS18_Plac | Placebo Comparator | Ferrous Sulphate (18 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose]) |
|
| FS18_Curc | Active Comparator | Ferrous Sulphate (18 mg/day elemental iron) and Curcumin 500 mg/day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ferrous Sulphate 65 mg | Dietary Supplement | Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content) Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation | Marker: Interleukin 6 (pg/mL), Interleukin 10 (pg/mL), Interleukin 1 beta (pg/mL) | Change in Interleukin 6, Interleukin 10 and Interleukin 1 beta (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation | Tumour Necrosis Factor alpha (pg/mL) | Change in Tumour Necrosis Factor alpha (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation | Marker: C-Reactive Protein (g/L) | Change in C-Reactive Protein (immunoassay) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated lipid peroxidation | Marker: thiobarbituric acid reactive substances (μM) | Change in thiobarbituric acid reactive substances (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated acute iron absorption | Marker: serum iron (μmol/L) | Change in serum iron (colorimetric analyser) from 0 and 180 minutes following supplementation |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated neurotrophic levels | Marker: Brain derived neurotrophic factor (BDNF) (ng/mL) | Change in BDNF (ELISA) from baseline to endpoint from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Male or Female
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Westminster | London | W1W 6UW | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000090463 | Iron Deficiencies |
| D005221 | Fatigue |
| ID | Term |
|---|---|
| D019189 | Iron Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C020748 | ferrous sulfate |
| D003474 | Curcumin |
| C012596 | turmeric extract |
| ID | Term |
|---|---|
| D036381 | Diarylheptanoids |
| D006536 | Heptanes |
| D000473 | Alkanes |
| D006839 | Hydrocarbons, Acyclic |
Not provided
Not provided
Allocation: Randomisation (block) Intervention Model: Parallel, Randomised placebo-controlled design Masking: Double-blind
Not provided
Not provided
Participants (and supplements) will be coded and randomly allocated (applied randomly by software [gender balanced[) to treatment arms to eliminate order effects and maintain research staff blinding.](streamdown:incomplete-link)
|
|
| Curcumin | Dietary Supplement | HydroCurc™ 500 mg formulated curcumin At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) |
|
|
| Placebo (Ferrous Sulphate) | Other | Microcrystalline cellulose Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) |
|
| Placebo (Curcumin) | Other | Microcrystalline cellulose Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) |
|
| Ferrous Sulphate 18mg | Dietary Supplement | Oral ferrous salt supplement Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content) Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules |
|
|
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated acute iron absorption | Marker: total iron binding capacity (μmol/L) | Change in total iron binding capacity (colorimetric analyser) from 0 and 180 minutes following supplementation |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status | Marker: serum iron (μmol/L) | Change in serum iron (colorimetric analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status | Marker: total iron binding capacity (μmol/L) | Change in total iron binding capacity (colorimetric analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status | Marker: Ferritin (ng/mL) | Change in ferritin (immunoassay) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status | Marker: Haemoglobin (g/dL) | Change in haemoglobin (whole blood analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status | Marker: Red blood cells (M/μL) | Change in red blood cells (whole blood analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated gastrointestinal effects | Subjective analysis including: Oral Iron Supplement Questionnaire | Change in reported subjective gastrointestinal effects from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated perception of fatigue | Subjective analysis including: Visual Analogue Scale for Fatigue (VAS-F). Scores range from 0 to 100 (the higher the score the greater the level of fatigue) | Change in VAS-F from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated perception of fatigue | Subjective analysis including: Fatigue Severity Scale (FSS). The total score of all answers indicates level of fatigue (a total score above ≥ 36 indicates fatigue). | Change in FSS from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint) |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D002396 | Catechols |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |